3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
5
Other hematologic neoplasm
3
Dermatologic
2
Plasma cell
1
Conditions
Multiple Myeloma
7
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Waldenstrom Macroglobulinemia
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
63
fludarabine phosphate
57
Peripheral Blood Stem Cell Transplantation
52
Mycophenolic Acid
42
Cyclosporine
35
Whole-Body Irradiation
34
Tacrolimus
32
Busulfan
30
Antilymphocyte Serum
30
Filgrastim
28
Radiotherapy
25
Methotrexate
23
Methylprednisolone
17
Melphalan
17
Etoposide
15
Cord Blood Stem Cell Transplantation
14
Therapeutics
10
Flow Cytometry
10
fludarabine
9
Sirolimus
8
Psychiatric Rehabilitation
8
Granulocyte Colony-Stimulating Factor
8
Cytarabine
8
Polymerase Chain Reaction
7
sargramostim
6
Rituximab
6
Alemtuzumab
6
Thiotepa
5
Prednisone
5
Carmustine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Burkitt Lymphoma
×
romidepsin
×
Plasma cell
×
Clear all
NCT01947140
2022-11-23
PDX+Romi
Columbia University
Phase 1/2
Completed
57 enrolled